Effect of inhibitors of protein kinase C on enhanced superoxide production of human leucocytes by ofloxacin and fleroxacin.
Matsumoto
T
T
Department of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Takahashi
K
K
Nagafuji
T
T
Kubo
S
S
Kumazawa
J
J
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000470:Alkaloids / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016576:Fleroxacin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology; D008163:Luminescent Measurements; D009504:Neutrophils / Q000201:enzymology / Q000378:metabolism*; D015242:Ofloxacin / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D019311:Staurosporine; D013481:Superoxides / Q000378:metabolism*
D000470:Alkaloids; D000890:Anti-Infective Agents; D004791:Enzyme Inhibitors; D007546:Isoquinolines; D010879:Piperazines; D013481:Superoxides; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D015242:Ofloxacin; D011493:Protein Kinase C; D019311:Staurosporine; D016576:Fleroxacin